Charles J. Casamento

Charles J. Casamento is a declared insider at 5 companies (senior executive); the most frequent names are Relmada Therapeutics, Inc., GridAI Technologies Corp. and International Stem Cell Corp. In total, 80 filings cover trades dated from 31 March 2016 to 22 October 2024.

Both buying and selling appear: 4 purchases worth €87k, against 28 sales worth €1.8M. On balance, insiders were net sellers of €1.8M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 33 share grants and 6 option exercises. Since January 2024: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €23k. 3 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was +0.7%. They describe history only and say nothing certain about the share price ahead.

The newest entry dates from 23 October 2024: a transaction, in Relmada Therapeutics, Inc. The most recent open-market purchase was published on 11 September 2024, 773 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.